Paper Details

  1. Home
  2. Paper Details

Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes.

Author: BerdejaJesus G, BorthakurGautam, EstrovZeev, FaderlStefan, GabrailNashat, Garcia-ManeroGuillermo, GodleyLucy A, JabbourElias, KantarjianHagop, KassalowLaurent, MaddipotiSirisha, NadeemAhmed, YangHui

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Low-dose decitabine showed promising results in patients with low- or intermediate-1-risk MDS.
Paper Details　
Original Abstract of the Article :
PURPOSE: This open-label, randomized phase II trial assessed efficacy and tolerability of two low-dose regimens of subcutaneous (SC) decitabine in patients with low- or intermediate-1-risk myelodysplastic syndrome (MDS). PATIENTS AND METHODS: Patients received decitabine 20 mg/m(2) SC per day for 3...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878053/

データ提供：米国国立医学図書館（NLM）

Decitabine for Myelodysplastic Syndromes: A New Oasis in the Desert of Hematological Disorders

The desert of hematological disorders is a challenging landscape to navigate, with patients often facing a range of debilitating symptoms. This study explores the efficacy and tolerability of decitabine, a drug used to treat certain types of leukemia, as a treatment for low- or intermediate-risk myelodysplastic syndromes (MDS). It's like discovering a new and potentially promising oasis in a vast and unforgiving desert.

Decitabine: A Potential Solution for Myelodysplastic Syndromes

The study found that decitabine, when administered in low-dose regimens, showed promising results in patients with low- or intermediate-risk MDS. It's like finding a well-spring of hope in a parched desert. The authors note that the drug was well-tolerated and achieved a significant overall improvement rate, suggesting its potential as a valuable treatment option for MDS.

Navigating the Desert of Hematological Disorders: A Path Toward Improved Treatments

This research provides a glimmer of hope for patients with MDS. It's like finding a new route through the desert, offering a chance for improved quality of life and potentially longer survival. Further research is needed to fully understand the long-term efficacy and safety of decitabine for MDS, but it represents a promising step forward in the quest for effective treatments for this challenging condition.

Dr. Camel's Conclusion

The desert of hematological disorders is vast and complex, but decitabine emerges as a potential oasis, offering a glimmer of hope for patients with MDS. Further exploration of this drug could lead to more effective treatments and a smoother journey through the desert of hematological challenges.

Date :
  1. Date Completed 2013-09-11
  2. Date Revised 2023-11-05
Further Info :

Pubmed ID

23733767

DOI: Digital Object Identifier

PMC4878053

Related Literature

Article Analysis
・Effects of decitabine injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.